This Article Full Text Full Text (PDF) CME: Take the course for this article: Immunotherapy for Epstein Barr Virus-Associated Cancers in Children eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Straathof, K. C.M. Articles by Heslop, H. E. Search for Related Content PubMed PubMed Citation Articles by Straathof, K. C.M. Articles by Heslop, H. E.

Immunotherapy for Epstein-Barr Virus-Associated Cancers in Children

Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA

Correspondence: Helen E. Heslop, M.D., Center for Cell and Gene Therapy, Baylor College of Medicine, 1102 Bates Street, Suite 1140, Houston, Texas 77030, USA. Telephone: 832-824-4662; Fax: 832-825-4668; e-mail: hheslop{at}bcm.tmc.edu

Latent Epstein-Barr virus (EBV) infection is associated with several malignancies, including Burkitt’s lymphoma, Hodgkin’s disease, nasopharyngeal carcinoma, and post-transplant lymphoproliferative disease (LPD). The presence of EBV antigens in these tumors provides a target for immunotherapy approaches, and immunotherapy with EBV-specific cytotoxic T cells (CTLs) has proved effective in post-transplant LPDs, which are highly immunogenic tumors expressing type III latency. The malignant cells in Hodgkin’s disease and nasopharyngeal carcinoma express type II latency and hence a more restricted pattern of EBV antigens. Trials with autologous EBV-specific CTL responses are under way in both of these diseases, and while some activity has been seen, no patient has yet been cured. This reduced CTL efficacy may reflect either downregulation of immunodominant EBV proteins, which are major CTL targets, or the ability of these tumors to evade the immune response by secreting inhibitory cytokines. Further improvement of EBV-specific CTL therapy for these type II latency tumors will require improved methods to activate and expand CTLs specific for the subdominant EBV genes expressed and to genetically modify the expanded CTLs to render them resistant to inhibitory cytokines. If these strategies to improve the therapeutic potential of immunotherapy for EBV-associated tumors prove successful, this type of treatment may be adapted to other tumors expressing known (viral) antigens.

Key Words. Epstein-Barr virus • Lymphoproliferative disease • Transplantation • Immunotherapy • Cytotoxic T cells

This article has been cited by other articles:

				A. Carbone, A. Gloghini, and G. Dotti EBV-Associated Lymphoproliferative Disorders: Classification and Treatment Oncologist, May 1, 2008; 13(5): 577 - 585. [Abstract] [Full Text] [PDF]

				J. Mrazek, S. B. Kreutmayer, F. A. Grasser, N. Polacek, and A. Huttenhofer Subtractive hybridization identifies novel differentially expressed ncRNA species in EBV-infected human B cells Nucleic Acids Res., May 11, 2007; 35(10): e73 - e73. [Abstract] [Full Text] [PDF]

				C. R. Kincaid, L. S. Nield, R. S. Moore, and F. G. Keller Posttransplant Lymphoproliferative Disease: A Case Report and Review for the General Pediatrician Clinical Pediatrics, May 1, 2007; 46(4): 287 - 291. [Abstract] [PDF]